Development of new drug candidates through the integration of computer-aided drug design with cell-based high-throughput assays.

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

6934.3;4 LSPP-LS

Titre du projet

Development of new drug candidates through the integration of computer-aided drug design with cell-based high-throughput assays.

Titre du projet anglais

Development of new drug candidates through the integration of computer-aided drug design with cell-based high-throughput assays.

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Development of new drug candidates through the integration of computer-aided drug design with cell-based high-throughput assays.
Résumé des résultats (Abstract) (Anglais)	The objectives of this collaboration are a) the development of computational methods for de novo drug design and for target-specific virtual screening of compound libraries, and b) their application for identifying in vivo inhibitors of pharmaceutically relevant targets. In silico-selected molecules will be tested for their effective activity towards pharmaceutically relevant targets in selective cell-based assays. This iterative, cyclic approach will enable the validation and improvement of the computational methods under development and the identification of potential ¿lead compounds¿ (drug precursors) that target disease-relevant proteins inside cells.

Catégorie

Texte

Description succincte
(Anglais)

Development of new drug candidates through the integration of computer-aided drug design with cell-based high-throughput assays.

Résumé des résultats (Abstract)
(Anglais)

The objectives of this collaboration are a) the development of computational methods for de novo drug design and for target-specific virtual screening of compound libraries, and b) their application for identifying in vivo inhibitors of pharmaceutically relevant targets. In silico-selected molecules will be tested for their effective activity towards pharmaceutically relevant targets in selective cell-based assays. This iterative, cyclic approach will enable the validation and improvement of the computational methods under development and the identification of potential ¿lead compounds¿ (drug precursors) that target disease-relevant proteins inside cells.